"A pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer a major new clinical trial concludes. The trial is a milestone in cancer treatment as the first to show the benefits of precision medicine in prostate cancer  with treatment matched to the particular genetic characteristics of a mans tumour. Olaparib the worlds first drug to reach the market targeted against inherited cancer mutations was found to benefit as many as a third of patients with prostate cancer including many who did not inherit cancer genes but whose tumours had acquired defects in DNA repair. An international consortium of researchers led by experts at The Institute of Cancer Research London and The Royal Marsden NHS Foundation Trust publish the trials findings in the New England Journal of Medicine today Wednesday. The trial called TOPARPA received support from a wide range of funders including Cancer Research UK the Prostate Cancer Foundation Stand Up To Cancer Prostate Cancer UK and the Movember Foundation. There was also support from the InvestigatorSponsored Study Collaboration between AstraZeneca and The NIHR Biomedical Research Centre at The Royal Marsden and the ICR the NIHR Cancer Research Network and Experimental Cancer Medicine Centre ECMC funding to the ICR and Royal Marsden and several other ECMC sites. In the trial  men with treatmentresistant advanced prostate cancer received olaparib and  of them  or  per cent  responded as defined by a set of clinical criteria. Olaparib stopped prostate cancer growth generating lasting falls in prostate specific antigen PSA levels falls in circulating tumour cell counts in the blood and radiological responses on CT scans and MRI. The clinical trial found that up to  per cent of men with advanced prostate cancer had tumours with defects in their systems for repairing DNA detected by genomic testing  and that these responded particularly well to olaparib. Of the  patients with detectable DNA repair mutations  responded very well to olaparib  accounting for the large majority of those who benefited from the drug. Most of these men who all had terminal prostate cancer with limited treatment options had disease control lasting much longer than expected in this group of patients. The results have led on to the start of TOPARPB a second part of this trial in which only men whose prostate cancers have detectable DNA repair mutations will receive olaparib. If the results are successful olaparib could become a standard treatment option for men with advanced prostate cancer and DNA repair mutations. The development of olaparib which is now owned by AstraZeneca was underpinned by scientific research carried out with funding from Cancer Research UK at The Institute of Cancer Research ICR and the University of Cambridge and clinical trials led by the ICR and The Royal Marsden and other institutions in the UK and overseas. It has had particularly strong results in phase III trials in patients who inherited mutations to the BRCA genes many of whom had breast or ovarian cancer. The drug a type of treatment called a PARP inhibitor was licensed last year for women with ovarian cancer and inherited BRCA mutations but so far has not been approved for use on the NHS by NICE or the Cancer Drugs Fund. Trial chief investigator Professor Johann de Bono Head of Drug Development at The Institute of Cancer Research London and The Royal Marsden NHS Foundation Trust said  Our trial marks a significant step forward in the treatment of prostate cancer showing that olaparib is highly effective at treating men with DNA repair defects in their tumours. It also proves the principle that we can detect prostate cancers with specific targetable mutations using genomic sequencing to deliver more precise cancer care by matching treatment to those men most likely to benefit. I hope it wont be long before we are using olaparib in the clinic to treat prostate cancer or before genomic stratification of cancers becomes a standard in this and other cancers. Study coleader Dr Emma Hall Deputy Director of the Cancer Research UKfunded Clinical Trials and Statistics Unit at The Institute of Cancer Research London which coordinated the study said This phase II clinical trial combined a highly targeted cancer drug with cuttingedge genomic sequencing. We showed that a subset of men whose tumours had mutations in their DNA repair machinery responded particularly well to treatment with olaparib. The next trial includes only men with these mutations in their tumours with the aim of proving that olaparib is highly effective for them. Dr Aine McCarthy science information officer at Cancer Research UK said Even though the number of men surviving prostate cancer is increasing its still the second most common cause of cancer death in UK men. This is partly because the disease is so hard to treat once it has spread around the body. This trial is exciting because it could offer a new way to treat prostate cancer by targeting genetic mistakes in cancers that have spread. The hope is that this approach could help save many more lives in the future. Howard R. Soule PhD executive vice president and chief science officer of the Prostate Cancer Foundation said TOPARPA is significant because it exploits the genetic similarities of prostate breast and ovarian cancers said. We are excited about this pioneering study because it demonstrates the tremendous crossover and wider applications in the research on these diseases. Dr. William Nelson covice chair of the SUC Scientific Advisory Committee and director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore Maryland said Understanding the link between prostate cancer and DNA repair mutations is incredibly important for patients and their families. We can identify prostate cancer patients who will benefit from drugs like olaparib and also help men and their families better understand their genetic risk of metastatic prostate cancer just as women with BRCA mutations do for breast and ovarian cancer. Notes to editors For more information contact Henry French on     henry.frenchicr.ac.uk mailtohenry.frenchicr.ac.uk. For enquiries out of hours please call   . The Institute of Cancer Research London is one of the worlds most influential cancer research institutes.  Scientists and clinicians at The Institute of Cancer Research ICR are working every day to make a real impact on cancer patients lives. Through its unique partnership with The Royal Marsden NHS Foundation Trust and benchtobedside approach the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally. The ICR has an outstanding record of achievement dating back more than  years. It provided the first convincing evidence that DNA damage is the basic cause of cancer laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancerrelated genes and discovering new targeted drugs for personalised cancer treatment. As a college of the University of London the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations charities and the general public.  The ICRs mission is to make the discoveries that defeat cancer. For more information visit http The Royal Marsden NHS Foundation Trust The Royal Marsden opened its doors in  as the worlds first hospital dedicated to cancer diagnosis treatment research and education. Today together with its academic partner The Institute of Cancer Research ICR it is the largest and most comprehensive cancer centre in Europe treating over  NHS and private patients every year. It is a centre of excellence with an international reputation for groundbreaking research and pioneering the very latest in cancer treatments and technologies.  The Royal Marsden with the ICR is the only National Institute for Health Research Biomedical Research Centre for Cancer. First awarded the status in  it was reawarded in . A total of  million is being provided over five years to support pioneering research work and is being shared out over eight different cancer themes. The Royal Marsden also provides community services in the London boroughs of Sutton and Merton and in June  along with the ICR the Trust launched a new academic partnership with Mount Vernon Cancer Centre in Middlesex.  Since  the hospitals charity The Royal Marsden Cancer Charity has helped raise over  million to build theatres diagnostic centres and drug development units. Prince William became President of The Royal Marsden in  following a long royal connection with the hospital. The Prostate Cancer Foundation PCF is the worlds leading philanthropic organization funding and accelerating prostate cancer research. Founded in  PCF has raised more than  million and provided funding to more than  research programs at nearly  cancer centers and universities. The PCF global research enterprise now extends to  countries. PCF advocates for greater awareness of prostate cancer and more efficient investment of governmental research funds for transformational cancer research. Its efforts have helped produce a fold increase in government funding for prostate cancer. For more information click here. About the Movember Foundation The Movember Foundation is a global charity raising funds and awareness for mens health. These funds deliver breakthrough research and support services to allow men to live longer healthier happier lives. Since  millions have joined the mens health movement raising more than  million and funding over  programs through impact investments focusing on four key areas prostate cancer testicular cancer poor mental health and physical inactivity. Movember is fully accredited by the Better Business Bureau and for the past three years has been named a Top  best NGO by The Global Journal. For more information please visit Movember.com. Movember is a registered c charity."